North America Breast Cancer Screening Tests Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The North America breast cancer screening tests market is segmented by Test (Genomic Tests and Imaging Test) and Geography.

Market Snapshot

breast cancer screening tests market
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 4.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of North American breast cancer screening tests market are the rising incidence of breast cancer, increasing government initiatives and support, and technological advancements.

Breast cancer is currently the leading cause of cancer-related deaths in women in North America. According to the American Cancer Society, in 2017, an estimated 252,710 new cases of invasive breast cancer were diagnosed among women. In addition, 63,410 cases of in situ breast carcinoma were diagnosed among women. Approximately 40,610 women and 460 men died from breast cancer in 2017, and the number of breast cancer cases is expected to increase in the coming years. It is estimated that the risk of an individual dying from breast cancer may increase in the coming years. Hence, the increase in the prevalence of breast cancer is a major factor contributing to the revenue growth of the market. Thus, owing to the above-mentioned factors, the market is expected to witness high growth over the forecast period.

Scope of the Report

As per the scope of the report, breast cancer screening is carried out to detect cancer in its early stages and ensure the timely treatment to the patients. There are different types of breast cancers depending on the type of breast cell that becomes cancerous. Breast cancer can affect different parts of the breast, such as the ducts and the lobes. The market is segmented by test and geography.

By Test
Genomic Tests
Imaging Test
Mammogram
Ultrasound
MRI
Tomography
Other Imaging Tests
Geography
North America
United States
Canada
Mexico

Report scope can be customized per your requirements. Click here.

Key Market Trends

Mammogram under the Imaging Test Segment is Expected to Hold the Largest Market Share

Mammograms are used in most cases of breast cancer screening. The United States Preventive Services Task ForceExternal (USPSTF) recommends that women aged between 50 and 74 years old and are at average risk for breast cancer should get a mammogram every two years. Furthermore, mammograms are the best way to find breast cancer early, and having regular mammograms can lower the risk of dying from breast cancer. Currently, a mammogram is the best way to find breast cancer in women. However, mammography is less likely to find breast tumors in women with dense breast tissue, as both tumors and dense breast tissues appear white on a mammogram, making it harder to find a tumor in such cases. Thus, there are other imaging techniques that are also likely to gain more popularity over the forecast period. Owing to the rising cases of breast cancer in the region, the market is expected to witness high growth over the forecast period.

1

Competitive Landscape

The market studied is moderately fragmented in nature, owing to the presence of several small and major market players. Some of the market players are Agendia BV, Fujifilm Holdings Corporation, Hologic Inc., Metabolomic Technologies Inc., Myriad Genetics, QIAGEN NV, Quest Diagnostics Incorporated, and Siemens Healthineers, among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Incidence of Breast Cancer

      2. 4.2.2 Increasing Government Initiatives and Support

      3. 4.2.3 Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Controversies Related to Mammography

      2. 4.3.2 Side Effects of Radiation during Screening Tests and Errors in Screening

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Test

      1. 5.1.1 Genomic Tests

      2. 5.1.2 Imaging Test

        1. 5.1.2.1 Mammogram

        2. 5.1.2.2 Ultrasound

        3. 5.1.2.3 MRI

        4. 5.1.2.4 Tomography

        5. 5.1.2.5 Other Imaging Tests

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Allengers Medical Systems Limited

      2. 6.1.2 Fujifilm Holdings Corporation

      3. 6.1.3 Hologic Inc.

      4. 6.1.4 GE Healthcare

      5. 6.1.5 Myriad Genetics

      6. 6.1.6 QIAGEN NV

      7. 6.1.7 Quest Diagnostics Incorporated

      8. 6.1.8 Siemens Healthineers

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Breast Cancer Screening Tests Market market is studied from 2018 - 2026.

The North America Breast Cancer Screening Tests Market is growing at a CAGR of 4.8% over the next 5 years.

Allengers Medical Systems Limited, Myriad Genetics, Siemens Healthineers, Hologic Inc., GENERAL ELECTRIC COMPANY are the major companies operating in North America Breast Cancer Screening Tests Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!